Gynecologic Oncology Program
The focus of the team of clinicians who form the Gynecologic Oncology Program at Smilow Cancer Hospital is to provide comprehensive and compassionate care for women with gynecologic cancers. Women diagnosed with vulvar, vaginal, cervical, uterine, fallopian tube, or ovarian cancers are provided with exceptional care from Yale’s experienced team of gynecologic oncologists at the hospital’s dedicated Women’s Center.
In addition, the team also treats soft tissue tumors of the pelvis, gestational trophoblastic disease, as well as women with precancerous changes that have been identified in the vulva, vagina, and cervix, including dysplasia and carcinoma in situ, or premalignant changes of the endometrium, including adenomatous hyperplasia.
The physicians of the Gynecologic Oncology Program offer a wide spectrum of advanced strategies for the diagnosis and treatment of gynecologic cancers, including colposcopy evaluation, conformal radiotherapy, and novel, targeted chemotherapies. The multidisciplinary program has experts from the obstetrics, gynecology, and reproductive sciences; radiation oncology; radiology and biomedical imaging; genetics; pathology; pharmacy; and social work. A dedicated patient coordinator facilitates patient appointments and communication, coordinates services, and supports each patient and their family.
Surgery for previously untreated gynecologic cancer
Surgery for benign disease
Surgery for complications
Discovery to Cure Program
Elena Ratner, MDGynecologic OncologyElena Ratner, MD, is a gynecologic oncologist specializing in ovarian malignancies. An advocate for cancer survivors, she is also co-founder and director of the Yale Medicine Sexual, Intimacy and Menopause Program (SIMS), one of the first programs in the country to focus on supporting cancer survivors coping with issues that may not be discussed in the other clinical settings. More than 22,000 American women are diagnosed with ovarian cancer each year. As a clinician working with these patients, Dr. Ratner stresses the importance of social networks during treatment, and helps facilitate one-on-one mentoring for those currently receiving treatment and those who have completed treatment. “We want these women to receive personal attention from somebody who has gone through this treatment before,” she says. “It is so important for women who need to know that they are not alone in this fight.” Dr. Ratner is an associate professor of obstetrics, gynecology and reproductive sciences at Yale School of Medicine. Her clinical research focuses on new targeted drugs for ovarian cancer that will provide truly personalized care, and on reversing chemotherapy resistance in ovarian and uterine cancers. She also studies chemotherapy targeted drug development, quality-of-life programs for patients and early cancer detection. Dr. Ratner is a recipient of multiple awards, including the 2015 Yale Cancer Center Award for Clinical Excellence.
News from Gynecologic Oncology Program
Gynecological Cancer Trials
- Gynecological Cancers, Head and Neck Cancers, Lung Cancer, Sarcoma Cancers, Cancer
A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
- Gynecological Cancers
A Phase 2 Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
- Ages18 years and older
- GenderFemale only